Related by context. All words. (Click for frequent words.) 76 ENMD # 74 Xanafide 74 pharmacodynamic properties 73 Azedra 73 oral prodrug 72 R#/MEM # 72 INCB# [001] 72 preclinical efficacy 72 PRTX 72 riociguat 72 preclinically 72 solithromycin 72 pharmacodynamic PD 71 radezolid 71 HuMax EGFr 71 favorable tolerability 71 PEG SN# 71 Tyrima 71 Traficet EN 71 potency selectivity 71 XmAb# 71 potent antiviral 71 Sym# 71 antiviral potency 71 teriflunomide 71 Symadex 70 TG# [003] 70 tolerability profiles 70 dose proportionality 70 S/GSK# 70 Archexin 70 tanespimycin 70 orally bioavailable 70 velafermin 70 delafloxacin 70 cytoprotective 70 MET amplification 70 OHR/AVR# 70 pomalidomide 70 CBLC# 70 PS# [001] 70 pharmacokinetic PK 70 pharmacokinetic PK profile 70 CIMZIA ™ 70 YONDELIS 70 busulfan 69 vitro cytotoxicity 69 Valortim ® 69 alvespimycin 69 antiviral efficacy 69 BNC# 69 oral FTY# 69 pan HDAC inhibitor 69 CCX# 69 MEK inhibitors 69 liposomal formulation 69 antiangiogenic activity 69 favorable pharmacokinetic 69 CIMZIA TM 69 mertansine 69 anti leukemic 69 PRT# 69 MGd 69 linear pharmacokinetics 69 histone deacetylase inhibitor 69 Virulizin ® 69 retapamulin 69 tezampanel 69 PSN# [002] 69 DAVANAT 69 TriRima 69 Pimavanserin 69 CA4P 69 ganetespib 69 JAK inhibitors 68 relapsed MM 68 NEUGENE 68 PXD# 68 HQK 68 ATL/TV# 68 fosbretabulin 68 pharmacokinetic profile 68 JAK inhibitor 68 tipifarnib 68 #ME# 68 SERMs 68 demonstrated antitumor activity 68 antitumour activity 68 HCV protease inhibitors 68 anticancer activity 68 GAMMAGARD 68 Panzem R NCD 68 potent inhibition 68 ANAVEX #-# [001] 68 OncoVEX GM CSF 68 rHuPH# 68 CG# [003] 68 anti amnesic 68 immunomodulating 68 dosage regimens 68 APOPTONE 68 pharmacodynamics PD 68 OMP #M# 68 pharmacodynamic endpoints 68 MAGE A3 ASCI 68 CORT # 68 Vidofludimus 68 erlotinib Tarceva ® 68 urocortin 2 68 ATL# [001] 68 PSMA ADC 68 melphalan prednisone 68 viral kinetics 68 Anticalins ® 68 elvucitabine 68 depsipeptide 68 GAP #B# 68 maximally tolerated dose 68 T#M mutation 68 Trofex 68 TPI ASM8 68 orally administered inhibitor 68 efficacy tolerability 68 OXi# 68 oral bioavailability 68 ARIKACE ™ 68 Seliciclib 68 IFN α 68 pharmacokinetic characteristics 68 vascular disrupting agent 68 neuroprotective properties 67 milatuzumab 67 bactericidal activity 67 cannabinor 67 indibulin 67 pharmacodynamic profile 67 CEQ# 67 A3 adenosine receptor 67 lomitapide 67 immune modulating 67 Cloretazine 67 metaglidasen 67 EndoTAG TM -1 67 Pharmacokinetic studies 67 GFT# 67 IGF 1R inhibitor 67 ruxolitinib 67 ISIS # 67 VAPRISOL 67 pharmacodynamic effects 67 Bezielle 67 antitumor efficacy 67 GLP toxicology studies 67 Carfilzomib 67 RLY# 67 CYT# potent vascular disrupting 67 HGS ETR2 67 pharmacokinetic interactions 67 pharmacodynamic 67 crizotinib PF # 67 antiviral activity 67 nonclinical studies 67 Omacetaxine 67 posaconazole 67 CRLX# 67 pharmacodynamic markers 67 vidofludimus 67 vinca alkaloid 67 obatoclax 67 DXL# 67 thymalfasin 67 plasma pharmacokinetics 67 selective modulator 67 HuLuc# 67 Panzem R 67 mapatumumab 67 potent antitumor 67 TBC# 67 Phase Ib study 67 potent antitumor activity 67 CTAP# Capsules 67 ara C 67 Chemophase 67 erythropoietic 67 flavopiridol 67 decitabine 67 GMX# 67 LHRH antagonists 67 bronchodilation 67 Aurora kinase 67 Arikace 67 ARIKACE 67 hA# 67 Valortim 67 AEGR 67 HGS# 67 HGS ETR1 67 INT# [002] 67 IMA# 67 BAL# [001] 67 Triapine R 67 Apoptone 67 BAL# [002] 67 isatoribine 67 potent anti angiogenic 67 ADAGIO study 67 insulin degludec 67 Antitumor Activity 67 systemically administered 67 QT QTc 66 HCV protease 66 BMS# 66 NXL# 66 Preclinical studies 66 Triolex 66 Pharmacokinetics PK 66 nucleoside analog 66 Anticalins 66 CaPre TM 66 VDAs 66 MYDICAR ® 66 vascular disrupting agents 66 pharmacokinetics PK 66 idarubicin 66 CDK inhibitor 66 IL #E 66 OMNARIS HFA 66 calcineurin inhibitors 66 antiangiogenic 66 inhaled iloprost 66 TRAIL R1 66 effector function 66 PEGylated interferon 66 Squalamine 66 uricase 66 azacytidine 66 dose proportional pharmacokinetics 66 forodesine 66 novel VDA molecule 66 NeuroSTAT ® 66 pharmacokinetic PK study 66 CLORETAZINE TM VNP#M 66 histone deacetylase HDAC inhibitor 66 Imprime PGG 66 DDP# 66 nanopharmaceutical 66 thalidomide Thalomid 66 pharmacodynamic parameters 66 basal bolus regimen 66 TRIOLEX 66 Non inferiority 66 pharmacokinetic properties 66 huN# DM1 66 neratinib 66 Aplidin 66 bendamustine 66 CANCIDAS 66 Thiovir 66 K ras mutations 66 pertuzumab 66 urate lowering 66 protease inhibitor PI 66 Radezolid 66 Interferon alpha 66 brostallicin 66 antitumor effects 66 HuMax CD4 66 CCR5 antagonist 66 ZOLINZA 66 Pharmacodynamic 66 ProSavin 66 antitumor 66 cariprazine 66 OncoVEX 66 aplindore 66 NP2 Enkephalin 66 GRN#L 66 SRT# [003] 66 BrachySil 66 Pemetrexed 66 antitumor activity 66 caspofungin 66 ulimorelin 66 Zoraxel 66 ritonavir boosted 66 PSN# [001] 66 CYC# 66 Golimumab 66 farletuzumab 66 refractory chronic lymphocytic 66 Tarceva TM 66 GLYX 66 ON #.Na 66 LY# [003] 66 ganaxolone 66 tumor necrosis 66 axitinib 66 rHuPH# enzyme 66 APTIVUS r 66 iSONEP 66 antiangiogenic agent 66 biodistribution 66 cilengitide 66 pharmacokinetic profiles 66 HCV replicon 66 oral gallium 66 CR# vcMMAE 66 JVRS 66 flurpiridaz F 66 Amphinex ® 66 cleavable linker 66 alefacept 66 protein kinase inhibitor 66 PD LID 66 galiximab 66 APTIVUS 66 Darinaparsin 66 subcutaneously administered 66 Panzem 66 EGFR HER2 66 pharmacokinetics pharmacodynamics 66 Kahalalide F 65 pharmacokinetic parameters 65 proteasome inhibitor 65 Multimeric 65 tolerability profile 65 evaluating tivozanib 65 analgesic efficacy 65 mesalamine granules 65 administered subcutaneously 65 PDE4 inhibitor 65 clevidipine 65 AKT inhibitor 65 antiproliferative effects 65 INCB# [003] 65 IRX 2 65 inhibitor RG# 65 myopathy rhabdomyolysis 65 SNT MC# 65 interferon IFN 65 rFIXFc 65 Anticalins R 65 rxRNA 65 Exelixis compounds 65 PKC# 65 mGluR2 NAM 65 AZILECT ® 65 tiotropium bromide 65 chemotherapeutic drug 65 bortezomib Velcade ® 65 CGEN # 65 vivo potency 65 MGN# 65 SCH # 65 Phase #b/#a trial 65 receptor tyrosine kinase inhibitor 65 AIR# [001] 65 novel prodrug 65 torezolid 65 Gleevec resistant 65 LSI #P 65 HCV protease inhibitor 65 Solorel TM 65 tipranavir 65 Valortim R 65 Combo Stent 65 AST ALT 65 IMiDs ® 65 Anticalin ® 65 CCR9 antagonist 65 cMET 65 Dasatinib 65 eniluracil 65 macrolide antibiotic 65 Omacetaxine mepesuccinate 65 telomerase inhibitor 65 Anticalin R 65 enzastaurin 65 RGB # 65 tubulin inhibitor 65 encapsulates siRNAs 65 nucleoside analogues 65 Aflibercept 65 Bendavia 65 oral rivaroxaban 65 Guanilib 65 clinically meaningful efficacy 65 Phase #b/#a 65 Talactoferrin 65 NVA# 65 rBChE 65 DermaVir 65 investigational humanized monoclonal antibody 65 #D#C# 65 UPLYSO 65 cytostatic 65 TLR agonists 65 cyclophilin inhibitor 65 Posiphen 65 plasma kallikrein inhibitor 65 alagebrium 65 anti fibrotic 65 DOXIL 65 relapsed SCLC 65 Perforomist ™ Inhalation Solution 65 targeted radiotherapeutic 65 #I TM# 65 dosing cohort 65 intranasal formulation 65 Aurexis 65 lumiliximab 65 HIF PH inhibitors 65 INC# 65 Blinatumomab 65 Inhaled AAT 65 CDDO Im 65 Onconase 65 YONDELIS R 65 faropenem 65 PROCHYMAL 65 xenograft models 65 KL4 surfactant 65 AEG# 65 trodusquemine 65 ORMD 65 ocular formulation 65 rhITF 65 polymerase inhibitor 65 orally dosed 65 gemcitabine Gemzar ® 65 Epothilones 65 Moxifloxacin 65 non nucleoside 65 LB# [003] 65 seliciclib 65 PEGPH# 65 selective androgen receptor modulator 65 XL# inhibits 65 CD# monoclonal antibody 65 ALGRX 65 transgene expression 65 JAK2 inhibitor 65 oral picoplatin 65 Vorinostat 65 talabostat 65 GRNCM1 65 eTag assays 65 NNRTI resistance 65 ceftazidime 65 Nanobody 65 atacicept 65 p# biomarker 65 LT NS# 65 regorafenib 65 selective adenosine 65 Vandetanib 65 Lenocta 65 Alocrest 65 MYCAMINE 65 trabectedin 65 safety tolerability pharmacokinetic 65 CCR2 65 immunomodulatory therapy 65 Epanova 65 secretory phospholipase A2 sPLA2 65 GHRH 65 iroxanadine 65 prucalopride 65 therapeutic monoclonal antibody 65 weekly subcutaneous injections 64 liposomal doxorubicin 64 ACAPODENE 64 radiolabeled TM# 64 Phase #b/#a clinical 64 Perifosine 64 torezolid phosphate 64 Technosphere Insulin 64 elotuzumab 64 Zalypsis 64 Synavive 64 pharmacokinetic equivalence 64 ularitide 64 vitro potency 64 TRV# [001] 64 genotypic resistance 64 AAG geldanamycin analog 64 Amplimexon 64 BZL# 64 5alpha reductase 64 inhaled TPI ASM8 64 octreotide acetate 64 rhIGFBP 3 64 nanoviricides 64 Pertuzumab 64 antiangiogenic agents 64 tumor xenograft models 64 CD# antibody [001] 64 Actilon 64 orally bioavailable mimics 64 paclitaxel poliglumex 64 Zysolin TM 64 nab paclitaxel 64 amrubicin 64 selective kinase inhibitor 64 NS#/#A protease 64 inecalcitol 64 Hsp# Inhibitor 64 EOquin 64 SELZENTRY 64 mGluR5 NAM 64 pharmacokinetic studies 64 ALN TTR 64 davunetide intranasal AL 64 NEUMUNE 64 TRO# 64 Anavex #-# 64 vivo validation 64 huC# DM4 64 Hsp# inhibition 64 hour bronchodilation 64 hyperphenylalaninemia HPA due 64 Relivar 64 therapeutically relevant 64 AGHD 64 ritonavir boosted protease inhibitor 64 TYSABRI natalizumab 64 novel peptide 64 Bortezomib 64 Pharmacokinetic 64 Zybrestat 64 CINQUIL 64 active moiety 64 Antiviral Activity 64 ESBA# 64 Sapacitabine 64 AQ4N 64 Capesaris 64 FOLFOX6 chemotherapy regimen 64 Tamibarotene 64 LEXIVA r 64 FFNS 64 HGS ETR1 mapatumumab 64 Epratuzumab 64 OMAPRO 64 topoisomerase II inhibitor 64 Deforolimus 64 interleukin IL -# 64 pharmacodynamic profiles 64 EndoTAGTM 1 64 selective agonist 64 visilizumab 64 PCK# 64 KNS # 64 varespladib 64 Protelos 64 potent anticancer 64 convenient dosing regimens 64 non nucleoside inhibitor 64 mTOR inhibitors 64 Psoraxine R 64 trastuzumab Herceptin ® 64 antitumor effect 64 biologic DMARD 64 ZK EPO 64 DermaVir Patch 64 Genz # 64 REP# 64 Darusentan 64 somatostatin analogue 64 Oral NKTR 64 DACH platinum 64 adipiplon 64 JAK2 inhibitors 64 selective inhibition 64 angiogenesis inhibitor 64 vismodegib 64 ANAVEX #-# [002] 64 renal toxicity 64 Ceplene/IL-2 64 partial agonist 64 immunomodulation 64 fluoropyrimidine 64 MAb 64 ASONEP 64 vorinostat 64 dose limiting toxicities 64 alicaforsen enema 64 pharmacokinetic pharmacodynamic 64 oral Xeloda 64 SAR# [004] 64 oblimersen 64 RezularTM 64 PREZISTA r 64 Cethromycin 64 pegylated liposomal doxorubicin 64 R baclofen 64 Telintra 64 Natalizumab 64 Revimmune 64 Aplidin R 64 AVE# 64 HDAC Inhibitor 64 bortezomib Velcade 64 Phase 1a clinical 64 THR beta agonist 64 IFN beta 64 generation purine nucleoside 64 genotypic 64 5 HT6 receptor 64 tafamidis 64 florbetaben 64 rhIL 7 64 preclinical pharmacokinetic 64 somatostatin analog 64 mecamylamine 64 IMC A# 64 vicriviroc 64 CCR9 64 SLx 64 myeloproliferative disorders 64 pathophysiological effects 64 MAP# 64 darunavir ritonavir 64 INGN 64 ART# 64 tigecycline 64 anti angiogenic agents 64 ponatinib 64 Plicera 64 Nilotinib 64 safinamide 64 rNAPc2 64 Vaxfectin 64 ALN VSP 64 immunomodulator 64 romidepsin 64 bortezomib Velcade R 64 vivo efficacy 64 INTELENCE 64 PHX# 64 cynomolgus monkeys 64 Zemplar Capsules 64 Quinamed 64 ELND# 64 T#I [002] 64 nucleoside polymerase inhibitor 64 Octreolin 64 trastuzumab Herceptin R 64 potent antiproliferative 64 imexon 64 temsirolimus Torisel ® 64 AzaSite Plus 64 beta Estradiol 64 pexiganan 64 EndoTAG TM 64 NEVO ™ 64 metastatic neuroendocrine tumors 64 docetaxel Taxotere R 64 angiotensin receptor blocker ARB 64 PI3K/Akt pathway inhibitor 64 intravenous dosing 64 nanomolar 64 antiproliferative activity 64 highly immunogenic 64 Palifosfamide 64 elvitegravir 64 BMS # 64 imetelstat 64 Altastaph 64 multitargeted 64 Angiolix 64 Ceflatonin 63 Androxal TM 63 imatinib therapy 63 CoFactor 63 p# inhibitor 63 5 Fluorouracil 63 receptor inhibitor 63 SPIRIVA HandiHaler 63 Reports Preclinical Data 63 imatinib Gleevec ® 63 selective antagonist 63 C1 INH 63 trastuzumab Herceptin 63 potent neuroprotective 63 XL# anticancer compounds 63 anti EGFR antibody 63 Ophena TM 63 atrasentan 63 Poly ICLC 63 Phase #/#a trial 63 novel anticancer 63 Pharmacokinetic PK 63 Pradefovir 63 dexpramipexole 63 HMG CoA reductase inhibitors 63 bevacizumab Avastin ® 63 CB1 antagonists 63 Hedgehog inhibitor 63 Gag polymorphisms 63 IgG1 antibody 63 sargramostim 63 BrachySil TM 63 RhuDex ® 63 corticosteroid dexamethasone 63 Curaxin CBLC# 63 Lp PLA 2 63 anti angiogenic agent 63 endothelin antagonist 63 tipranavir r 63 virologic responses 63 sorafenib Nexavar 63 molecularly targeted 63 EKC Cide 63 Irinotecan 63 lenalidomide Revlimid R 63 TELINTRA 63 AZILECT R 63 immunomodulatory 63 Elagolix 63 tolerability pharmacokinetics 63 LibiGel ® 63 MoxDuo ® IR 63 CYT# 63 epigenetic therapies 63 PhG alpha 1 63 eprotirome 63 radiolabeled 63 Abiraterone acetate 63 uric acid lowering 63 Maribavir 63 BAY #-# 63 Telatinib 63 liposome formulation 63 IFN alpha 63 ISTODAX 63 imatinib resistance 63 immunomodulatory properties 63 SERCA2a 63 myelofibrosis polycythemia vera 63 ULORIC 63 plasma renin activity 63 noninfectious uveitis 63 budesonide foam 63 Factor VIIa 63 kidney urologic 63 Spiegelmer ® 63 Tarvacin 63 R roscovitine 63 prostanoid 63 piperacillin tazobactam 63 brivaracetam 63 entinostat 63 elacytarabine 63 etoposide 63 beta lactams 63 long acting muscarinic 63 replicon 63 FK# 63 telaprevir VX 63 triphendiol 63 clinically meaningful improvement 63 DCCR 63 meropenem 63 Ceftaroline 63 Zolinza 63 anti androgens 63 azacitidine 63 ciclesonide 63 QVAR ® 63 anticancer compound 63 EP #R 63 Aviptadil 63 omega interferon 63 HSP# inhibitor 63 B7 H3 63 immunostimulatory 63 PEG PAL 63 cardiac toxicity 63 micafungin 63 immune modulatory 63 antimicrobial efficacy 63 INCB# [002] 63 #HT#A 63 Prodarsan ® 63 TAKSTA 63 XL# XL# 63 TNF Tumor Necrosis Factor 63 ataluren 63 Pegasys ® 63 AMD# [003] 63 Stedivaze 63 Antiangiogenic 63 thetreatment 63 MTP inhibitor 63 glycosylation profile 63 PRX# 63 aleglitazar 63 Tezampanel 63 Aliskiren 63 AZT zidovudine Retrovir 63 lesinurad 63 Phase Ib clinical 63 potent cytotoxic 63 antiapoptotic 63 Anthracyclines 63 binding affinity 63 levodopa induced dyskinesia 63 teduglutide 63 Menerba 63 Nanobodies ® 63 antitumoral 63 beta lactam antibiotic 63 liposomal formulations 63 estramustine 63 tezampanel NGX# 63 Bevirimat 63 ascending dose 63 nucleotide analog 63 synthetic retinoid 63 HspE7 63 picomolar 63 CINTREDEKIN BESUDOTOX 63 EDEMA3 trial 63 TOLAMBA 63 potent inhibitor 63 DP b# 63 efaproxiral 63 bronchodilatory 63 pegylated IFN 63 antithrombotic 63 PEGylated interferon beta 1a 63 Teriflunomide 63 apremilast 63 Arsenic trioxide 63 sorafenib tablets 63 mTOR inhibitor 63 colesevelam HCl 63 menadione 63 docetaxel Taxotere ® 63 CRx 63 SYN# 63 sunitinib Sutent ® 63 Durezol 63 nucleoside reverse transcriptase inhibitor 63 MEK inhibitor 63 Pafuramidine 63 azoles 63 bexarotene 63 IAP inhibitor 63 PEGylated 63 Lisofylline LSF 63 Interferon beta 63 Tolvaptan 63 Phase 1b trial 63 novel histone deacetylase 63 NOD SCID mice 63 EOquin TM 63 chemopreventive agent 63 NOX E# 63 RH1 63 steroid dexamethasone 63 amikacin 63 MORAb 63 genotoxicity 63 oral antiviral 63 LAB CGRP 63 silico prediction 63 mg kg dose 63 aclidinium 63 AVN# [001] 63 XYOTAX TM 63 taxane resistant 63 EndoTAG 63 clobazam 63 Lixivaptan 63 Cannabinor 63 haematologic 63 PNP inhibitor 63 TACI Ig 63 Aclidinium 63 lapatinib Tykerb 63 recombinant interferon 63 REG1 63 antiproliferative 63 oxaliplatin Eloxatin 63 Tanespimycin 63 gemcitabine cisplatin 63 NGX# 63 sCD# 63 anticoagulant reversing agent 63 targeting CD# 63 FOLPI 63 BRAF inhibitor 63 cytokine refractory 63 beta 1a 63 PEGylated anti 63 Excellarate 63 monomeric 63 ATACAND 63 Proxinium TM 63 Pharmacokinetic parameters 63 Fulvestrant 63 lipid lowering therapies 63 muscarinic 63 low dose cytarabine 63 EGFR antibodies 63 tolerated dose MTD 63 Elotuzumab 63 Tolerability 63 Catena ® 63 PK PD 63 GSK# [001] 63 fluoroquinolone antibiotic 63 PARP inhibitor 63 FOLOTYN ® 63 inhaled corticosteroid ICS 63 pramlintide metreleptin combination 63 immune stimulatory 63 Nanobodies 63 inhaled AAT 63 Vidaza azacitidine 63 JAK3 63 IMiDs R 63 IPLEX 63 alpha#beta# integrin 63 Panzem NCD 63 GV# [001] 63 volociximab 63 DFMO 63 dosing frequency 63 ELACYT 63 ascending doses 63 Plenaxis TM 63 protein tyrosine phosphatase 63 TH# [003] 63 #beta HSD1 63 potent inhibitory 63 echinocandin 63 RiVax 63 NPM1 63 gefitinib Iressa 63 microtubule targeting 63 μg dose 63 taxane refractory 63 Capecitabine 63 histone deacetylase HDAC 63 myeloproliferative diseases 63 Targretin 63 Neuradiab 63 SARMs 63 JAK Inhibitor 63 Voreloxin 63 Doxil ® 63 mimetics 63 vivo preclinical 63 isoproterenol 63 CCR5 mAb 63 pitavastatin 63 amphotericin B 63 Mitoxantrone 62 pharmacologically active isomer 62 glucagon receptor 62 Anidulafungin 62 PLX cells 62 humanized anti 62 IMiDs 62 ATL# [002] 62 MNTX 62 EpCAM 62 zileuton 62 ALV# 62 2 methoxyestradiol 62 interferon alfa 2b 62 PREZISTA rtv 62 nanomolar potency 62 Elocalcitol 62 Mipomersen 62 pharmacokinetic 62 phase IIb clinical 62 dacetuzumab 62 AeroLEF TM 62 nanomolar range 62 bardoxolone methyl 62 Varespladib 62 tranilast 62 Nanobody ® 62 Hsp# inhibitors 62 Corgentin 62 Preclinical studies suggest 62 ROTARIX 62 Safinamide 62 GPx 62 lenalidomide dexamethasone 62 sPLA2 62 Bicifadine 62 bevirimat 62 Alagebrium 62 elastase